UNIVERSITY OF THE PACIFIC | Thomas J. Long School of Pharmacy

Day One BIOPHARMACEUTICALS

Fellowship in Industry Program 2022

UNIVERSITY OF THE PACIFIC | Thomas J. Long School of Pharmacy

About University of the Pacific

University of the Pacific is a nationally ranked university with a long tradition of dedicated teaching, small class sizes, practical experience and vibrant residential life. The breathtaking main campus in Stockton, California is home to eight schools and colleges, with more than 80 majors and programs of study. The Thomas J. Long School of Pharmacy opened in 1955 and has a long-standing record for producing high-quality pharmacists with the option for dual degree programs (PharmD/PhD or PharmD/MS) and post-doctoral academic fellowships. Over the last nine years, average annual faculty research grants in the School totaled more than one million dollars with extensive participation in NIH and NSF grants and more than 95 percent of faculty publishing. The School touts a unique decentralized Advanced Pharmacy Practice Experience (APPE) model with seventeen regions having faculty members bolstering teaching, scholarship and service.

Learn more at pacific.edu/pharmacy

Mission

The mission of the Thomas J. Long School of Pharmacy is to prepare students for lifelong success in health careers by providing an excellent, student-centered learning environment. We aspire to develop leadership skills in our students and a strong commitment to their professions, to interprofessional collaboration, and to society. These efforts are assisted by linkages across the University of the Pacific professional and liberal arts programs. We support outstanding professional and graduate teaching, research and other scholarly activity, and services as a means of achieving our mission.

Welcome Message from the Associate Dean of Professional Programs

Dear Prospective Fellow,

We are so pleased that you are considering the University of the Pacific's Fellowship in Industry Program (FIP) in partnership with Day One Biopharmaceuticals. The goal of this program is to increase industry fellowship opportunities offered through partnerships between biopharmaceutical organizations and universities on the West Coast.

At University of the Pacific, the first charter university in California, we value individualized training and focus on leadership development, which are exemplified by our partnership with Day One. For more than 60 years, the Thomas J. Long School of Pharmacy has been training health care professionals who are problem-solvers, innovators and leaders. Our faculty dives deeper, using research to challenge the status quo of health care and education.

As an FIP fellow, you will be fully immersed in a clinical science role at Day One supporting innovative drug development. In addition, you will have opportunities to work alongside the faculty and preceptors at the University, Veteran Affairs Palo Alto Health Care System and Travis Air Force Base where you can engage in research collaboration, grant and manuscript development, teaching, student and resident mentoring and other professional development activities.

I highly encourage you to contact our FIP Director, Dr. Sachin Shah, and the exceptional team of program mentors so you can appreciate how this program can further your future success.

Best Regards,

Allen Shek, PharmD
Professor of Pharmacy Practice
Associate Dean of Professional Programs
Thomas J. Long School of Pharmacy
University of the Pacific



Ready from Day One and every day after.

Day One BIOPHARMACEUTICALS

We're Day One. A biopharmaceutical company that's ready to make a real difference for children with cancer, by making sure modern targeted treatments can get to those who need them most. We're ready to introduce ground-breaking new medicines. Ready to be dedicated, long-term partners. Ready to solve the urgent challenges faced by children with cancer. From Day One and every day after.

Learn more at dayonebio.com

About Day One Biopharmaceuticals

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company created to find and develop new therapies to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Day One aims to re-envision cancer drug development and redefine what is possible for all people living with cancer—regardless of age—starting from Day One.

Our name was inspired by "The Day One Talk" which is a life altering moment for children and their families after they first learn about a new diagnosis and treatment plan. We exist to dramatically change the outlook for families who receive the devastating news of a cancer diagnosis or other life-threatening diseases.

Day One is headquartered in Brisbane, CA, just north of Northern California's major biotechnology hub in South San Francisco. With over 100 full time employees, Day One is led by a senior team with deep expertise in oncology, pediatric, and rare disease development, registration and commercialization. Our culture is built around a shared vision and purpose, and welcome prospective fellows to learn more about the impact they can make on the lives of patients through their work at Day One.

Learn more

Day One BIOPHARMACEUTICALS

Our Pipeline

Product Candidate	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Recent & Anticipated Milestones
Tovorafenib (DAY101) Type II Pan-RAF Inhibitor ✓ FDA Breakthrough Therapy Designation for relapsed pLGG ✓ FDA Rare Pediatric Disease Designation (PRV Eligible) for pLGG ✓ FDA Orphan Drug Designation for gliomas ✓ EC Orphan Designation for gliomas	Relapsed pLGG		FIREFLY-1[1] (pivotal)			**Pivotal cohort enrollment complete**: May 2022 **Initial data presented**: June 2022 **Topline data expected**: Q1 2023
	Frontline pLGG		FIREFLY-2 (pivotal)			**Trial Initiation**: June 2022 **First patient dosing expected**: 2H 2022
	RAF-altered solid tumors[2] (monotherapy)		FIRELIGHT-1*			**First patient dosed**: November 2021
Pimasertib MEK 1/2 Inhibitor	MAPK-altered solid tumors[3] (Combo w/tovorafenib)		FIRELIGHT-1*			**First patient dosed**: May 2022

**Includes patients ≥12 years of age. 1 FIREFLY-1 Arm 1 expected to support registration. 2 DAY101 adult monotherapy Phase 1 dose escalation and expansion trial previously completed. 3 Pimasertib Phase 1 dose escalation and expansion trial previously completed. pLGG, pediatric low-grade glioma. Tovorafenib and Pimasertib are investigational products. Safety and efficacy have not been established by any health authority.*

Mindful Innovation

Inspired by the urgent needs of children with cancer, Day One creatively and intentionally develops new medicines for people of all ages living with life-threatening diseases

Message from the Executive Sponsor of Day One's Clinical Science Fellowship

Dear Prospective Fellow,

Thank you for your interest in exploring Day One's inaugural Clinical Science fellowship provided in partnership with the University of the Pacific, Thomas J. Long School of Pharmacy. Our post-doctoral, PharmD curriculum will offer experiences in oncology clinical development that support Day One's patient-focused, innovative drug development programs.

We are offering passionate, motivated PharmD graduates the opportunity to gain the hands-on industry experience and mentorship required for successful careers in drug development. With PharmDs currently contributing across all levels and in different functional areas of Day One, you will find an ideal, supportive educational environment. Upon completion of the two-year program, you will have skills and training required for a successful and exciting career as a clinical researcher.

On behalf of Day One, we welcome you to apply to this program and help us advance our mission of addressing the urgent needs of children and adults living with cancer.

Best Regards,

Michael Cox, PharmD, MHSc, BCOP
Vice President, Clinical Development
Day One Biopharmaceuticals

Day One BIOPHARMACEUTICALS

Day One Fellowship | Clinical Science (Oncology)

The Clinical Science team at Day One supports the mission of delivering new therapies to those with the greatest unmet needs by execution of clinical development plans with the highest level of integrity and urgency. The Fellow will contribute to the scientific aspects of Day One's oncology clinical programs, with opportunities spanning Phases I - III studies. Through hands-on experience, the Fellow will develop a core understanding of protocol design, scientific oversight of trials, and interpretation and reporting of study results. In addition, the Fellow will build scientific expertise in the fields of targeted therapy, central nervous system tumors, and pediatric drug development.

The Fellow will also have opportunities to collaborate with other functional groups such as Translational Sciences, Clinical Operations, and Regulatory Science on critical projects to support Day One's development plans.

Activities:

- Partner with Clinical Scientists and Medical Monitors to ensure scientific oversight for Day One's clinical studies
- Author key scientific documentation including protocols, informed consent forms, medical data review plans, investigator's brochures, and clinical study reports
- Collaborate with cross functional experts on key safety and regulatory submissions
- Enhance scientific communication skills through the development of presentations to internal and external audiences
- Develop a comprehensive understanding of the fundamentals of clinical research and Good Clinical Practice (GCP)

Program Mentors

Daniel Da Costa, PharmD
Director, Clinical Science

Ben Tsao, PharmD
Associate Director, Clinical Science

UNIVERSITY OF THE PACIFIC | Thomas J. Long School of Pharmacy

iCOR innovative clinical & outcomes research

Brief Overview

Fellowship in Industry Program

The University of the Pacific's Fellowship in Industry Program (FIP) was founded in 2017 with the goal of providing exceptional biopharmaceutical industry training for PharmD graduates. We strive to deepen domain specific technical skills while sharpening soft skills for all fellows. The fellows will spend 90 percent of their time at Day One. The balance of time will be spent on professional development activities at the University.

University of the Pacific's FIP is unique for several reasons. The program:

1. Integrates pharmaceutical industry training with a blend of academia or hospital practice experiences.
2. Enhances research capabilities via engagement in the Innovative Clinical and Outcomes Research (iCOR) program.
3. Embraces the innovative culture of the San Francisco Bay Area, home to many health care startup companies.

Learn more at pacific.edu/pharmacy/icor

Program Mentors

Sachin A. Shah, PharmD, FACC, FAHA
Professor of Pharmacy Practice
Regional Coordinator – Travis AFB
Director, Fellowship in Industry Program

Jeremy Lim, PharmD
Associate Director, Fellowship in Industry Program
Thomas J. Long School of Pharmacy

Activities at the Thomas J. Long School of Pharmacy

The fellow will have clinical faculty status at University of the Pacific, Thomas J. Long School of Pharmacy in Stockton, California.

They may be engaged in:

- Conducting research in collaboration with faculty
- Attending professional development meetings
- Developing grant and manuscript writing skills
- Advising Pacific's Industry Pharmacists Organization (IPhO) student chapter
- Mentoring rotational students in professional development and industry opportunities
- Participating in teaching activities (e.g. industry elective, research elective)

Program Mentors

Allen Shek, PharmD
Professor of Pharmacy Practice
Associate Dean of Professional Programs

Kate M. O'Dell, PharmD, BCPS, FCSHP
Professor of Pharmacy Practice

Nancy N. Nguyen, PharmD, BCPS, AAHIVP, FCSHP
Clinical Professor of Pharmacy Practice
Regional Coordinator – Palo Alto

Sachin A. Shah, PharmD, FACC, FAHA
Professor of Pharmacy Practice
Regional Coordinator – Travis AFB
Director, Fellowship in Industry Program

Select Publications from Former FIP fellows:

Posters and Publications

- **Oh E,** Owen R, Poon V, Wong K, Yoshida K. PKPD Modeling to Characterize Placebo and Treatment Effect of Omalizumab for Chronic Spontaneous Urticaria (CSU). Abstract at American Conference on Pharmacometrics (ACOP) Annual Meeting 2022; Aurora, CO, 2022.
- Dayal P, **Dimond C**, Yang X, Kent M, Rizzo S, Mohan D. Defining the Frequent Exacerbator Phenotype During a Pandemic in COPD. Abstract at American College of Chest Physicians (CHEST) Annual Meeting 2021; Orlando, FL 2021.
- **Dimond C**, Shah S, Dovan K, Tran B, Hsu K, Pham K, O'Dell K. Effects of Nelumbo nucifera extract on anxiety symptoms in individuals with moderate-to-severe anxiety. (Under Peer-review)
- **Liu X**, **Kawakatsu S**, Tran B, Tran B, Manzenero L, Shih E, Shek A, Lim J, Shah SA. Differences in Glucose Readings Between Right Arm and Left Arm Using a Continuous Glucose Monitor. Poster at American Heart Association-Scientific Sessions, 2020, Virtual Conference. (Abstract #13259). Published as a paper in Journal of Diabetes Science and Technology. https://pubmed.ncbi.nlm.nih.gov/33955249/
- **Kawakatsu S**, Zhu R, Zhang W, Tang MT, Lu T, Quartino A, Kågedal M. Longitudinal Placebo Response Modeling in Patients with Ulcerative Colitis. Poster at American Conference on Pharmacometrics; Aurora, CO, 2020.
- **Kawakatsu S**, Bruno R, Kågedal M, Li C, Girish S, Joshi A, Wu B. Confounding Factors in Exposure-Response Analyses and Mitigation Strategies for Monoclonal Antibodies in Oncology. https://pubmed.ncbi.nlm.nih.gov/33217012/
- Sathyamoorthya M, Verduzco-Gutierrez M, **Varanasi S**, et al. Enhanced external counterpulsation for management of symptoms associated with long COVID. American Heart Journal Plus: Cardiology Research and Practice. January 2022.
- Kunder R, Yeh F, Chinn L, Dash A, Lewin-Koh N, **Kim N**, Fredrickson J, Yoshida K, Chen S, Wilson M, and Wong C. Multiple Doses of an Anti-FGFR1/KLB Bispecific Antibody (BFKB8488A) are Associated with a Decrease in Hepatic Fat in Patients with NAFLD. Poster at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2019; Boston, MA 2019.
- **Kim N**, Pham K, Shek A, Lim J, **Liu X**, Shah SA. Differences in Glucose Level Between Right Arm and Left Arm Using Continuous Glucose Monitors. Published in Digital Health. https://pubmed.ncbi.nlm.nih.gov/33224517/

On-Going Clinical Research

- Time In Range Difference between Arms using Continuous Glucose Monitors in Patients with Diabetes. PIs: **Allen Lat**, PharmD, Sarika Mujumdar, PharmD
- Effects of a natural caffeinated energy drink on blood glucose parameters. PI: **Elise Oh**, PharmD.

Fellowship Eligibility Requirements

A candidate must:

- ❑ Be a permanent resident or citizen of the United States
- ❑ Have earned a PharmD from an ACPE accredited college of pharmacy before the start of the fellowship term

Application Process

Candidates must submit via email (pharmfip@pacific.edu) all the following application materials by the deadline listed on the University's website:

- ❑ Letter of intent
- ❑ Updated curriculum vitae (CV)
- ❑ Three (3) letters of recommendation emailed directly from letter writer to FIP director
- ❑ One professional writing sample that demonstrates medical writing ability
- ❑ Unofficial pharmacy school transcript emailed to FIP director
- ❑ All application materials should be addressed to:
  Sachin A. Shah, PharmD, FACC, FAHA
  Director, Fellowship in Industry Program
  Professor of Pharmacy Practice
  Thomas J. Long School of Pharmacy

See application deadline at pacific.edu/pharmacy/fellowships/day-one



Day One
BIOPHARMACEUTICALS